Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × Metformin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Triple Negative Breast Neoplasms 3 Obesity 3 Lung Neoplasms 3 Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Kidney Neoplasms 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Intraductal, Noninfiltrating 2 Breast Carcinoma In Situ 2 Breast Cancer Female 2 Brain Neoplasms 2 Weight Loss 1 Waldenstrom Macroglobulinemia 1 Small Cell Lung Carcinoma 1 Sleep Wake Disorders 1 Sezary Syndrome 1 Rectal Neoplasms 1 Racism 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peripheral Nervous System Diseases 1 Ovarian Neoplasms 1 Mycosis Fungoides 1 Multiple Endocrine Neoplasia Type 1 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡